Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
Matthew R. Smith
Consultant or Advisory Role - Amgen; Bayer
Research Funding - Amgen
Robert E. Coleman
Honoraria - Amgen; Bayer; Novartis
Research Funding - Novartis
Expert Testimony - Novartis
Laurence Klotz
Honoraria - Amgen; Ferring; Janssen; Sanofi
Research Funding - Ferring
Kenneth B. Pittman
No relevant relationships to disclose
Piotr Milecki
No relevant relationships to disclose
Rachel Wei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Arun Balakumaran
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Karim Fizazi
Consultant or Advisory Role - Amgen; Novartis
Honoraria - Amgen; Novartis